Sudden Cardiac Death Risk Stratification in Patients With Nonischemic Dilated Cardiomyopathy  by Goldberger, Jeffrey J. et al.
Journal of the American College of Cardiology Vol. 63, No. 18, 2014
 2014 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.12.021Heart Rhythm DisordersSudden Cardiac Death Risk Stratification
in Patients With Nonischemic
Dilated Cardiomyopathy
Jeffrey J. Goldberger, MD, MBA,* Haris Subacius, MA,* Taral Patel, MD,* Ryan Cunnane, MD,y
Alan H. Kadish, MDz










accepted DeObjectives TCenter for Cardiovascula
of Medicine, Feinberg
inois; ySection of Cardio
hicago, Illinois; and the
Dr. Goldberger is Direct
is a not-for-proﬁt think
r honoraria from Boston S
s have reported they have
close.
pt received July 6, 2013; r
cember 3, 2013.he purpose of this study was to provide a meta-analysis to estimate the performance of 12 commonly reported risk
stratiﬁcation tests as predictors of arrhythmic events in patients with nonischemic dilated cardiomyopathy.Background Multiple techniques have been assessed as predictors of death due to ventricular tachyarrhythmias/sudden death in
patients with nonischemic dilated cardiomyopathy.Methods Forty-ﬁve studies enrolling 6,088 patients evaluating the association between arrhythmic events and predictive tests
(baroreﬂex sensitivity, heart rate turbulence, heart rate variability, left ventricular end-diastolic dimension, left
ventricular ejection fraction, electrophysiology study, nonsustained ventricular tachycardia, left bundle branch block,
signal-averaged electrocardiogram, fragmented QRS, QRS-T angle, and T-wave alternans) were included. Raw event
rates were extracted, and meta-analysis was performed using mixed effects methodology. We also used the
trim-and-ﬁll method to estimate the inﬂuence of missing studies on the results.Results Patients were 52.8  14.5 years of age, and 77% were male. Left ventricular ejection fraction was 30.6  11.4%.
Test sensitivities ranged from 28.8% to 91.0%, speciﬁcities from 36.2% to 87.1%, and odds ratios from 1.5 to 6.7.
Odds ratio was highest for fragmented QRS and TWA (odds ratios: 6.73 and 4.66, 95% conﬁdence intervals: 3.85 to
11.76 and 2.55 to 8.53, respectively) and lowest for QRS duration (odds ratio: 1.51, 95% conﬁdence interval: 1.13
to 2.01). None of the autonomic tests (heart rate variability, heart rate turbulence, baroreﬂex sensitivity) were
signiﬁcant predictors of arrhythmic outcomes. Accounting for publication bias reduced the odds ratios for the various
predictors but did not eliminate the predictive association.Conclusions Techniques incorporating functional parameters, depolarization abnormalities, repolarization abnormalities, and
arrhythmic markers provide only modest risk stratiﬁcation for sudden cardiac death in patients with
nonischemic dilated cardiomyopathy. It is likely that combinations of tests will be required to optimize risk
stratiﬁcation in this population. (J Am Coll Cardiol 2014;63:1879–89) ª 2014 by the American College of
Cardiology FoundationSee page 1890Sudden cardiac death (SCD) occurs in 184,000 to 462,000
people annually in the United States (1). Although the
majority have ischemic heart disease, a substantial fraction
have nonischemic dilated cardiomyopathy (NIDCM). Pri-
mary prevention of SCD focuses on identifying high-risk
subpopulations of patients who could beneﬁt from morer Innovation and the Division of Cardiology,
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evised manuscript received November 16, 2013,intensive therapies, such as the implantable cardioverter-
deﬁbrillator (ICD), which reduces mortality in selected
subgroups of patients (2,3).NIDCM is the second leading cause of left ventricular
systolic dysfunction (4) with a 12% to 20% estimated mor-
tality at 3 years (2,3,5). Death occurs from both advanced
heart failure and SCD. In a meta-analysis of ICD trials in
patients with NIDCM, there was a 31% mortality reduction
with ICD therapy (6), indicating that SCD due to ven-
tricular tachycardia (VT)/ventricular ﬁbrillation (VF) ac-
counts for a substantial proportion of the mortality in this
disease, although the ICD may also prevent SCD secondary
to bradyarrhythmias in some patients.
Abbreviations
and Acronyms
BRS = baroreﬂex sensitivity
CI = conﬁdence interval
EPS = electrophysiology
study
HRT = heart rate turbulence
HRV = heart rate variability
ICD = implantable
cardioverter-deﬁbrillator
LVEDD = left ventricular end-
diastolic dimension








SCD = sudden cardiac death
TWA = T-wave alternans
VF = ventricular ﬁbrillation
VT = ventricular tachycardia
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1880Both the potential for im-
proved survival with the ICD
and the challenge of optimally
deploying this therapy to the
patients who will beneﬁt from it
highlight the importance of risk
stratiﬁcation in NIDCM. Des-
pite the plethora of available
techniques, no deﬁnitive test or
set of tests is recommended for
this population (1). Most studies
that have addressed this issue are
either small and nonrandomized
or are challenged by the use of a
variety of endpoints. The aim of
this analysis was to aggregate the
results of available studies in an
attempt to provide a platform for
future development of a risk
stratiﬁcation algorithm.Methods
Literature search. We sought to
identify all published reports eval-
uating predictors of arrhythmicevents in patients with NIDCM. A primary prevention
population was targeted, but studies that included a small
proportion of secondary prevention patients (<20%) were
also included.
The search was performed with the MEDLINE elec-
tronic database and was supplemented with manual searches
through the reference lists of the publications. Key words
used were “nonischemic cardiomyopathy” and “idiopathic
dilated cardiomyopathy.” The scope of the database search
was further deﬁned by the following predictors: baroreﬂex
sensitivity (BRS), electrophysiology study (EPS), heart rate
turbulence (HRT), heart rate variability (HRV), left ven-
tricular end-diastolic dimension (LVEDD), left ventricular
ejection fraction (LVEF), nonsustained ventricular tachy-
cardia (NSVT), QRS duration, fragmented QRS, QRS-T
angle, signal-averaged electrocardiogram (SAECG), and
T-wave alternans (TWA).
Only English language studies involving human subjects
published from inception to 2012 were considered. If mul-
tiple publications from the same patient cohort were
discovered, we used the data from the latest reports with the
largest numbers of appropriate subjects and outcomes. Un-
published data from the DEFINITE (DEFIbrillators in
Non-Ischemic cardiomyopathy Treatment Evaluation) trial
(3) were available to the investigators and were also included
in the summary results.
The initial list of candidate publications was constructed
by crossing all studies including NIDCM populations with
each of the predictor categories. The abstracts of the iden-
tiﬁed reports were examined for presence of arrhythmicoutcomes and follow-up endpoints. Studies that did not
report follow-up data or did not use predictors of interest
were excluded from further consideration. Full texts of the
publications identiﬁed at this stage were independently
examined by 2 investigators, raw data were extracted where
possible, and the results were independently veriﬁed by a
third author. Studies in which outcomes for NIDCM pa-
tients were not reported separately from ischemic cardio-
myopathy patients were excluded (Fig. 1).
Data extraction. Raw counts of true positives, false posi-
tives, false negatives, and true negatives were extracted from
each study whenever possible. When raw data were not re-
ported, proportions of positive cases, event rates, risk ratios,
sensitivity, and speciﬁcity were used to calculate the raw
numbers. Some of these statistics were on the basis of sur-
vival analyses rather than on contingency tables; therefore,
derived estimates were included in this report when they
matched the reported data to within 10%. This margin of
error was deemed acceptable as predictor effectiveness was
on the basis of survival curves rather than raw numbers in
many reports.
In addition to raw counts, we extracted baseline patient
characteristics, medical covariates, medications, endpoints
used, and length of follow-up from each report. In studies
that included both NIDCM and ischemic cardiomyopathy
patients, baseline demographic characteristics were used only
if reported separately for NICDM.
Evaluation of test results. Several of the studied parame-
ters had nonuniform deﬁnitions of abnormal results, exam-
ples of which are noted below. Patients with positive and
indeterminate TWA ﬁndings were generally analyzed in the
same group and compared against patients with negative
TWA in the majority of the reports, although 5 studies
excluded patients with indeterminate TWA. Positive EPS
was variably deﬁned and included inducible monomorphic
and polymorphic VT as well as VF. Cut-offs for abnormal
LVEDD varied between 64 mm and 70 mm, and for
LVEF, between 25% and 35%. Abnormal QRS duration
was deﬁned by a cut-off of 110 ms to 120 ms. The cut-offs
for abnormal HRV varied between 50 ms and 120 ms for
SDNN (standard deviation of NN [normal RR] intervals).
Abnormal BRS was deﬁned by >3 or >6 ms/mm Hg. Two
studies used both slope and onset criteria to deﬁne abnormal
HRT, whereas the third only used slope.
Endpoints. When available, arrhythmic endpoints were
utilized: sudden or arrhythmic death, cardiac arrest, appro-
priate ICD therapy, and documented VT/VF. If arrhythmic
endpoints were not reported, total mortality was included.
Finally, studies in which nonarrhythmic events (i.e., cardiac
or heart failure mortality, heart transplantation) were
included in composite endpoints with arrhythmic events
were also accepted, but in the vast majority of studies a
primary arrhythmic endpoint was noted.
Data analysis. Baseline characteristics from the included
studies were summarized by using weighted averages of
means and standard deviations for continuous variables.
Figure 1 Flow Chart of Study Selection Process
BRS ¼ baroreﬂex sensitivity; EPS ¼ electrophysiology study; HRT ¼ heart rate turbulence; HRV ¼ heart rate variability; LVEDD ¼ left ventricular end-diastolic diameter; LVEF ¼
left ventricular ejection fraction; NSVT ¼ nonsustained ventricular tachycardia; QRS-T ¼ QRS-T angle; SAECG ¼ signal-averaged electrocardiogram; TWA ¼ T-wave alternans.
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1881Patient counts were summed and the ﬁnal percentage was
calculated directly from raw numbers. Not all studies re-
ported on each of the identiﬁed patient characteristics;
therefore, different studies are incorporated in the summary
for each patient characteristic, and the resulting statistics
provide only a rough estimate of the population summarized
in this report.
Estimates of 3-year event rates for each study were on the
basis of the reported number of events and mean or median
follow-up time. Exponential survival (constant mortality rate
through time) was assumed in calculating 3-year event rates.
Aggregate 3-year event rates for each predictor category were
calculated as average study duration weighted by the number
of patients in each study.
Data from individual studies were combined to produce
aggregated estimates separately for each predictor category
using the random-effects model in SAS PROC MIXED
(SAS Institute, Cary, North Carolina). Log-odds ratios were
used as measures of effect, and their respective variances werespeciﬁed as known diagonal elements in the R covariance
matrix. For studies with no patients in at least 1 of the cells, 0.5
was added to all 4 elements of the 2-by-2 summary tables.
Meta-analytic summaries on the basis of ordinary risk ratios
were also calculated using the Mantel-Haenszel random-ef-
fects method. Finally, the “trim and ﬁll” strategy for estimating
the number of studies omitted because of publication bias and
adjusting for the latter by symmetrical imputation of the
omitted studies was used (7).Results
Patient characteristics. Forty-ﬁve studies enrolling 6,088
patients with NIDCM were summarized in this meta-
analysis (Table 1). Age was 52.8  14.5 years (within-
study averages ranged between 39 and 65 years); 77% were
male (range 57% to 94%). Average New York Heart As-
sociation functional class was 2.3  1.0 (range 1.5 to 3.4).
LVEF was 30.6  11.4%; LVEDD was 66.1  8.9 mm.
Table 1 Summaries of Patient Characteristics for Studies Included in Meta-Analysis
No. of Studies n Summary Range
Study characteristics
Follow-up, months 45 6,088 33.6  19.9 10–96
Estimated 3-yr event rate 18.9  12.8 4.5–79.3
Patient characteristics
n 45 6,088 135.3  125.4 15–572
Age, yrs 36 4,953 52.8  14.5 38.9–64.5
Male 38 5,089 76.7 57–94
NYHA functional class 27 4,277 2.3  1.0 1.5–3.4
Diabetes mellitus 8 1,912 16.5 0–23
Hypertension 5 1,721 27.8 10.5–39
Duration of CHF, months 4 867 10.4  17.5 4–25
Left bundle branch block 11 2,247 30.1 19–42.6
Right bundle branch block 7 1,244 2.7 0–9
Nonsustained ventricular tachycardia 15 2,239 42.7 14.5–100
Syncope 11 1,206 6.8 0–54
Implantable cardioverter-deﬁbrillator 11 2,315 15.6 0–100
History of atrial ﬁbrillation 20 3,185 17.1 0–41
Heart rate, beats/min 3 805 72.8  12.1 70–81
Systolic blood pressure, mm Hg 4 747 123.5  15.9 120–127
Diastolic blood pressure, mm Hg 3 568 75.9  12.2 74–78
LVEDV, mm 2 486 205.6  76.6 171.0–208.7
LVESV, mm 2 486 146.9  64.7 121.0–149.2
LVEF, % 28 4,098 30.6  11.4 17–45
LVEDD, mm 17 2,657 66.1  8.9 61–73
LVESD, mm 1 446 55.1  9.6 NA
Peak oxygen uptake, ml/kg/min 2 560 16.4  5.8 14.8–16.8
PCWP, mm Hg 6 390 16.4  10.0 14–22
Cardiac index, l/min/m2 5 369 2.6  0.77 2.1–2.9
Medications
ACE inhibitor 18 3,445 62.4 8.5–100
Amiodarone 21 3,753 80.4 38.8–100.0
Beta-blockers 19 3,604 71.0 0.0–98.8
Digoxin 18 3,408 58.6 19–97
Diuretic agents 4 733 35.3 16.0–74.5
Spironolactone 16 2,792 12.3 0–22
Summary data are mean  SD or %.
ACE ¼ angiotensin-converting enzyme; CHF ¼ congestive heart failure; LVEDD ¼ left ventricular end-diastolic dimension; LVEDV ¼ left ventricular
end-diastolic volume; LVEF ¼ left ventricular ejection fraction; LVESD ¼ left ventricular end-systolic dimension; LVESV ¼ left ventricular end-systolic
volume; NA ¼ not available; NYHA ¼ New York Heart Association; PCWP ¼ pulmonary capillary wedge pressure.
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1882Performance of individual risk stratiﬁcation tests. The
results for each predictor grouped by category are shown in
Figure 2 (8–59), and summarized in Table 2. (A detailed list
by predictor is given in Online Table 1).
Raw endpoint rates varied between 4.8% and 46.6%;
however, these event rates reﬂect highly variable follow-up
durations (10 months to 8 years) and are not, therefore,
directly comparable. Weighted average follow-up duration
was 33.6  19.9 months for all studies (median 29, inter-
quartile range 19 to 39 months). The LVEF studies had the
longest weighted average follow-up duration (41 months,
range 14 to 96 months), and TWA had the shortest (24
months, range 13 to 52 months). Using exponential survival
assumption, estimated average 3-year event rate across all
studies was 18.9  12.8%. Estimated 3-year event rates for
individual studies ranged from 4.5% to 79.3%. Whenaggregated by predictor, the variability of the 3-year mor-
tality estimate decreasedd11.8% to 21.5%.
Table 2 summarizes the sensitivities and speciﬁcities for
the 12 predictor tests. Sensitivities ranged from 28.8% to
91.0%, and speciﬁcities ranged from 36.2% to 87.1%.
Performance of risk stratiﬁcation tests was compared by
estimating the odds ratio (OR) for patients with and without
the predictor.TheORswerehighest for fragmentedQRS (OR:
6.73, 95% conﬁdence interval [CI]: 3.85 to 11.76) and TWA
(OR: 4.66, 95%CI: 2.55 to 8.53) and lowest for QRS duration
(OR: 1.51, 95%CI: 1.13 to 2.01).All predictors had signiﬁcant
OR for identifying events in the functional, arrhythmia, de-
polarization, and repolarization categories (p  0.014 for all).
Only 1 study was available for QRS-T angle, which was also a
signiﬁcant predictor of adverse events (p¼ 0.006). None of the
3 autonomic-based predictors was predictive.
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1883To provide visual evaluation of the potential for publica-
tion bias, in Figure 2, the studies are arranged in increasing
order of their contribution to the meta-analytic estimate from
top to bottom. Because estimates of the predictor effects are
more precise when more information is available, one would
expect a “funnel” pattern on the plots. As the precision of the
estimates increases, the scatter on the horizontal dimension
should decrease toward the bottom of the ﬁgure.
The OR plot for TWA is representative in this regard.
Three of the 4 studies with highest weights report OR
estimates that fall below the meta-analytical estimate. The
CI for the heaviest weighted study does not even overlap the
meta-analytic estimate. Conversely, studies with less preci-
sion all report estimates above the meta-analytic estimate of
OR. This bias for less precise studies with higher rather than
lower estimates of effect to be available in the published
literature is often attributed to the tendency for smaller
studies with signiﬁcant p values to be submitted and/or
accepted for publication. Consequently, the meta-analytic
estimate for the effect of TWA on arrhythmic events
should be regarded as optimistic.
Quantitative evaluation of publication bias using the trim-
and-ﬁll method (R andL estimators were used) suggested that
missing studies may exist in the HRV, LVEF, NSVT, QRS,
and TWA predictor categories. The L estimator indicated
that for the 12 reports in the TWA section, 11 unreported
counterparts are likely. After imputing the missing studies
with symmetrical mirror images of the published reports, the
meta-analytic estimates of the OR were reduced in each of
these categories (HRV OR: 1.21, 95% CI: 0.72 to 2.05, p ¼
0.25; LVEF OR: 2.73, 95% CI: 1.99 to 3.76, p < 0.001;
NSVT OR: 2.06, 95% CI: 1.48 to 2.96, p < 0.001; QRS
duration OR: 1.46, 95% CI: 1.10 to 1.94, p ¼ 0.013; TWA
OR: 2.03, 95% CI: 1.25 to 3.29, p ¼ 0.004). These ﬁndings
show that the effect for the variables evaluated in this report
could be as small as half the size estimated from the published
reports as a result of publication bias. It is noteworthy, how-
ever, that the p values remained relatively unchanged, and the
overall qualitative conclusions about the effectiveness of the
predictors were not affected by trim-and-ﬁll imputation.
Discussion
The present study demonstrates that a variety of risk strat-
iﬁcation techniques are useful in identifying SCD risk in
NIDCM patients. These techniques incorporate functional
parameters, depolarization and repolarization abnormalities,
and arrhythmic markers. On the basis of the available data,
disturbances in autonomic function do not appear promising
at this point for SCD risk stratiﬁcation in NIDCM. At best,
the odds ratio for any 1 predictor is generally in the range of
2 to 4, precluding their usefulness in isolation for individual
patient decisions (60–62). Still, given the fact that there are
so many predictors along different pathophysiological
pathways, these ﬁndings provide a platform upon which
multidimensional risk assessment can be further developed.In contrast to ischemic cardiomyopathy, the pathophysi-
ology of ventricular arrhythmias in NIDCM is less well
understood. Arrhythmogenesis is likely multifactorial and
may be related to structural changes such as ﬁbrosis and left
ventricular dilation as well as to primary and secondary
electrophysiological changes; these may result in ventricular
tachyarrhythmias due to reentry, abnormal automaticity, and
triggered activity. Focal mechanisms seem to underlie the
isolated premature ventricular complexes (PVCs) and NSVT
that originate in the subendocardium (63). However, when
sustained monomorphic VT occurs in NIDCM, reentry
within the myocardium is the most common mechanism
(64–66). Similar to ischemic cardiomyopathy, the substrate
for reentry in NIDCM is probably scar-based (67,68).
Recent magnetic resonance imaging data conﬁrm that the
presence and extent of myocardial ﬁbrosis correlate with risk
of adverse outcomes, including appropriate ICD therapy
(69,70). Another ﬁnding is the presence of low-voltage
electrograms along the reentry circuit, consistent with scar
(67,68). The pathogenesis of polymorphic VT/VF in
NIDCM is less understood. The overarching theme is that
arrhythmogenesis in NIDCMmay be due to the interplay of
several variables and that no single abnormality can fully
explain the process. This idea is consistent with the ﬁndings
of the present report, which highlights the potential utility of
risk markers representing a wide range of pathophysiological
processes in NIDCM.
The present analysis consolidates the best available liter-
ature on risk stratiﬁcation for SCD in NIDCM. This
population of patients has been less studied than patients
with ischemic cardiomyopathy. The cumulative number of
patients included for each technique in the present report
ranges from 359 to 2,692, whereas a similar analysis from
2001 involving patients with coronary artery disease
included a range of 4,022 to 9,883 for each technique (71).
Similarly, among the 5 largest primary prevention ICD
trials, there were 3,596 patients with ischemic cardiomy-
opathy versus 1,262 patients with NIDCM (72). That re-
ﬂects, in part, the lower prevalence of NIDCM; the annual
incidence has been reported to be 5 to 8 cases per 100,000
persons, with a prevalence of 36 to 40 per 100,000 persons
(4). In contrast, ischemic heart disease is thought to be
responsible for 60% to 75% of heart failure incidence and
prevalence in the United States. As patients with NIDCM
are younger (4,73), appear to have a better prognosis, and
receive less overall beneﬁt from the ICD (6) than patients
with ischemic cardiomyopathy, the potential role for risk
stratiﬁcation is even greater.
Current guidelines for ICD implantation in patients with
NIDCM rely solely on the imprecise parameters of depressed
LVEF and New York Heart Association functional class,
criteria that are neither speciﬁc nor sensitive enough to
adequately capture the highest risk patients. Indeed, in the
present analysis, the OR for LVEF was 2.86, with sensitivity
and speciﬁcity of 71.1% and 50.5%, respectively. This
ﬁnding is consistent with epidemiologic observations that
Figure 2 Raw and Meta-Analytic Odds Ratios With 95% Conﬁdence Intervals by Study and Predictor Category
(A) For autonomic parameters, data are shown for baroreﬂex sensitivity (BRS) (8,9), heart rate turbulence (HRT) (10–12), and heart rate variability (HRV) (8,9,13,14). (B) For
functional parameters, data are shown for left ventricular end-diastolic diameter (LVEDD) (15–18) and left ventricular ejection fraction (LVEF) (3,9,15–24). (C) For arrhythmia
parameters, data are shown for electrophysiology (EP) study (18,22,25–37) and nonsustained ventricular tachycardia (NSVT) (3,9,13,15,17,18,20,23–26,34,36–42). (D) For
depolarization parameters, data are shown for fragmented QRS (43,44), QRS duration/left bundle branch block (LBBB) (3,8,9,18,20,23,26,39,45,46), and signal-averaged
electrocardiogram (3,9,15,17,18,35,47–50). (E) For repolarization parameters, data are shown for T-wave alternans (9,15,17,47,51–58). Continued on the next page
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1884many SCDs occur in patients with LVEF >35% (74–76). In
fact, no technique has yet emerged as precise enough to affect
clinical decision making. The best predictors of adverse
outcomes include TWA, LVEDD, EPS, SAECG, LVEF,
QRS duration, and NSVT. Fragmented QRS and QRS-T
angle were also signiﬁcant, but were only addressed in 1 or
2 studies. Notably, TWA was the most sensitive predictor in
the group, and EPS was the most speciﬁc. In contrast, HRV,
HRT, and BRS were not statistically signiﬁcant predictors.
This ﬁnding suggests that autonomic dysfunction may be
a less important or variable factor in the pathophysiologyof ventricular arrhythmias in NIDCM than the other pro-
cesses described in the preceding text.
The present analysis can help guide future efforts at
improving risk stratiﬁcation in NIDCM by providing a
starting point for which techniques to consider. Bailey et al
(71) demonstrated that a multiple-tier risk stratiﬁcation
approach in patients with coronary artery disease can, in
theory, be highly discriminative with 92% of the population
stratiﬁed into either a high- or low-risk group with 2-year
predicted major arrhythmic event rates of 41% or 3%,
respectively. Similarly, a risk score comprising 5 clinical
Figure 2 Continued
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1885variables, each of which had a hazard ratio <2, performed
well for intermediate-term risk stratiﬁcation in patients
enrolled in the MADIT-II (Multicenter Automatic Deﬁ-
brillator Implantation Trial-II) trial (77). Other reports also
highlight the utility of combining predictors for risk strati-
ﬁcation (78,79) To achieve adequate risk stratiﬁcation for
clinical decision making with a high level of discrimination,
ORs of >15 to 20 are likely necessary (61,80). Clearly, that
cannot be achieved with the currently available techniques
when used individually.
Study limitations. Several limitations need to be
acknowledged. Foremost, the majority of the studies
included were small, with sample sizes <100. Evidence of
publication bias of reporting only positive studies with small
sample sizes was detected in several categories. Skewed pa-
tient populations were also noted; namely, only Asians were
included in the 2 studies evaluating fragmented QRS. Some
important studies were undoubtedly excluded, such as theTWA substudy from the SCD-HeFT (Sudden Cardiac
Death in Heart Failure Trial) (81) because of the inability to
obtain raw data from the information provided. It is notable
that after accounting for “missing studies” by the imputation
technique, the OR for TWA was 2.03 with 95% CI of 1.25
to 3.29, a range that certainly encompasses this report that
was not included in the present analysis. In addition, a va-
riety of endpoints were used in these studies. Many were
arrhythmia speciﬁc, but several included all-cause mortality,
cardiovascular mortality, worsening heart failure, or heart
transplantation. While every attempt was made to focus on
arrhythmic endpoints, some endpoints in this analysis may
represent nonarrhythmic events, which may reduce the
speciﬁcity of the parameters. Even the arrhythmic endpoints
are not equivalent as appropriate ICD shocks are not a
surrogate for arrhythmic SCD. In addition to the various
endpoints, there was heterogeneity in the deﬁnition of
abnormal test results among the included studies. Although
Table 2 Meta-Analytic Summaries of Test Performance by Predictor Category
Predictor Studies Events/n (%)
Calculated
3-Yr Event Rate (%) Prev. (%) Sens. (%) Spec. (%) PPA (%) NPA (%) RR (95% CI) OR (95% CI) p Value
Autonomic
BRS 2 48/359 (13.4) 17.0 52.9 64.6 48.9 16.3 89.9 1.80 (0.63–5.16) 1.98 (0.60–6.59) 0.23
HRT 3 66/434 (15.2) 18.6 32.3 47.0 70.4 22.1 88.1 2.12 (0.77–5.83) 2.57 (0.64–10.36) 0.16
HRV 4 83/630 (13.2) 15.6 43.1 55.4 58.8 16.9 89.7 1.52 (0.84–2.75) 1.72 (0.80–3.73) 0.13
Functional
LVEDD 4 62/427 (14.5) 17.1 42.9 66.1 61.1 22.4 91.4 2.85 (1.70–4.79) 3.47 (1.90–6.35) 0.014
LVEF 12 293/1,804 (16.2) 16.9 53.1 71.7 50.5 21.9 90.2 2.34 (1.85–2.96) 2.87 (2.09–3.95) <0.001
Arrhythmia
EPS 15 146/936 (15.6) 21.5 15.4 28.8 87.1 29.2 86.9 2.09 (1.30–3.35) 2.49 (1.40–4.40) 0.004
NSVT 18 403/2,746 (14.7) 15.7 45.5 64.0 57.7 20.7 90.3 2.45 (1.90–3.16) 2.92 (2.17–3.93) <0.001
Depolarization
QRS/LBBB 10 262/1,797 (14.6) 14.7 35.7 45.4 65.9 18.5 87.6 1.43 (1.11–1.83) 1.51 (1.13–2.01) 0.010
SAECG 10 152/1,119 (13.6) 19.9 36.9 51.3 65.4 18.9 89.5 1.84 (1.18–2.88) 2.11 (1.18–3.78) 0.017
Frag. QRS 2 65/652 (10.0) 11.8 25.6 61.5 78.4 24.0 94.8 5.16 (3.17–8.41) 6.73 (3.85–11.76) <0.001
Repolarization
QRS-T 1 97/455 (21.3) 25.0 62.2 74.2 41.1 25.4 85.5 1.75* (1.16–2.65) 2.01* (1.22–3.31) 0.006*
TWA 12 177/1,631 (10.9) 15.8 66.8 91.0 36.2 14.8 97.0 3.25 (2.04–5.16) 4.66 (2.55–8.53) <0.001
*1 study available; raw rather than meta-analytical value is reported.
BRS ¼ deﬁne BRS; Frag. ¼ fragmented; EPS ¼ electrophysiology study; HRT ¼ heart rate turbulence; HRV ¼ heart rate variability; LBBB ¼ left bundle branch block; NPA ¼ negative predictive accuracy; NSVT ¼ nonsustained ventricular tachycardia; OR ¼ odds ratio; PPA ¼
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1887these limitations preclude precise quantitative conclusions
about the predictive value of each test, the qualitative results
are consistent and informative. Furthermore, this analysis
highlights the need for more uniform deﬁnitions and
reporting of studies evaluating factors predicting SCD risk.
Finally, a range of medical therapy was used in these studies
and the interaction of medical therapy with the prognostic
value of these tests may be a signiﬁcant factor.
Conclusions
The present analysis provides important insights into risk
stratiﬁcation in NIDCM. The current model for risk
stratiﬁcation in NIDCM is handicapped by both limited
sensitivity and limited speciﬁcity. On the basis of available
literature, there are promising risk assessment tools that are
both widely available and easily measurable. Going forward,
each of these tools will have to be studied in a coordinated
fashion prospectively in larger trials. There are tremendous
opportunities to ameliorate the public health problem of
SCD and simultaneously improve cost effectiveness. As
most SCDs occur in patients who do not meet current
criteria for an ICD, broadening the criteria will certainly
bring more of the at-risk population under the safety net, but
if that is not done using a method with high discrimination,
it will create a tremendous burden on the health care system.
Similarly, if a signiﬁcant number of patients receiving ICDs
with the current criteria can be risk stratiﬁed to a low-risk
group for whom there is no survival beneﬁt from the de-
vice, these patients can avoid the risk of device implantation
and eliminate an unnecessary cost to the health care system.
Using these data to develop successful risk stratiﬁcation
approaches should, therefore, be a high priority.
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